Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Rallybio ( (RLYB) ) is now available.
On July 8, 2025, Rallybio Corporation announced the sale of its interest in the REV102 program, an ENPP1 inhibitor for hypophosphatasia, to Recursion Pharmaceuticals for up to $25 million. This transaction, which includes an upfront payment of $7.5 million, is expected to extend Rallybio’s cash runway to mid-2027, allowing the company to focus on advancing its pipeline and leveraging its drug development expertise.
The most recent analyst rating on (RLYB) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Rallybio stock, see the RLYB Stock Forecast page.
Spark’s Take on RLYB Stock
According to Spark, TipRanks’ AI Analyst, RLYB is a Underperform.
Rallybio’s stock is under significant pressure due to poor financial performance characterized by operational losses and negative cash flows, compounded by bearish technical indicators and challenging valuation metrics. Without revenue growth, the sustainability of operations is at risk, making it a highly speculative investment in its current state.
To see Spark’s full report on RLYB stock, click here.
More about Rallybio
Rallybio Corporation is a clinical-stage biotechnology company focused on developing and commercializing transformative therapies for patients with severe and rare diseases. The company has a pipeline targeting diseases with unmet medical needs in areas like complement dysregulation and hematology, with key programs including a C5 inhibitor for immune platelet transfusion refractoriness and a preclinical antibody for iron overload diseases. Rallybio is headquartered in New Haven, Connecticut.
Average Trading Volume: 173,766
Technical Sentiment Signal: Sell
Current Market Cap: $14.17M
Learn more about RLYB stock on TipRanks’ Stock Analysis page.